NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies

Reuters

2025/10/22

NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies

NanoViricides Inc. announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577936256"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577936256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577936256?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577936256","market":"nz","top_or_hot":-1,"title":"NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-22 20:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NNVC","symbol_name":"NanoViricides Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL8lDxP0:1","article_id":"2577936256","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577936256","pubTimestamp":1761137122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NanoViricides Inc. announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.Disclaimer: This news brief was created by Public Technologies  using generative artifi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NNVC":"NanoViricides Inc.","BK4568":"美国抗疫概念","BK4139":"生物科技"},"translate_title":"NanoViricides报告NV-387在临床前研究中对麻疹具有很强的抗病毒活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NNVC":0.9},"content_text":"NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies\n    \n\nNanoViricides Inc. announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}